https://akceatx.com/

Contact Information:

Kaitlin Camp
Cell:  505-456-4549
kcamp@akceatx.com

Trent Miller
Cell: 952-300-5156
tmiller@akceatx.com

 

Virtual Exhibit Hall Home

Akcea Therapeutics, a wholly owned subsidiary of Ionis Pharmaceuticals, is a biopharmaceutical company headquartered in Boston, Massachusetts focused on developing and commercializing medicines to treat patients with serious and rare diseases. Akcea is commercializing TEGSEDI® (inotersen) in the U.S., E.U., Canada and Brazil, and WAYLIVRA® (volanesorsen) in the E.U., as well as advancing a mature pipeline of novel medicines, pelacarsen (AKCEA-APO(a)-LRx), vupanorsen (AKCEA-ANGPTL3-LRx), AKCEA-APOCIII-LRx, and AKCEA-TTR-LRx, with the potential to treat multiple diseases. All six drugs were discovered by Ionis, a leader in antisense therapeutics, and are based on Ionis’ proprietary antisense technology. Additional information is available at www.akceatx.com.

Tegsedi PI

Covid Leave Behind

Tegsedi MOA